Enhancing the QUAlity and Transparency Of health Research
Use your browser's Back button to return to your search results
|Reporting guideline provided for?
(i.e. exactly what the authors state in the paper)
|Reporting of rheumatic and musculoskeletal disease (RMD) exercise trials.|
|Full bibliographic reference||Metsios GS, Brodin N, Vlieland TPMV, Van den Ende CHM, Stavropoulos-Kalinoglou A, Fatouros I, van der Esch M, Fenton SAM, Tzika K, Moe RH, van Zanten JJCSV, Koutedakis Y, Swinnen TW, Veskoukis AS, Boström C, Kennedy N, Nikiphorou E, Fragoulis GE, Niedermann K, Kitas GD; IMPACT-RMD Consortium. Position Statement on Exercise Dosage in Rheumatic and Musculoskeletal Diseases: The Role of the IMPACT-RMD Toolkit. Mediterr J Rheumatol. 2021;32(4):378-385.|
(full-text if available)
|Read the full-text of this reporting guideline.|
|Reporting guideline acronym||IMPACT-RMD Toolkit|
|Study design||Clinical trials, Experimental studies|
|Applies to the whole report or to individual sections of the report?||Intervention (exposure)|
|Record last updated on||May 20, 2022|
Some reporting guidelines are also available in languages other than English. Find out more in our Translations section.
For information about Library scope and content, identification of reporting guidelines and inclusion/exclusion criteria please visit About the Library.
Visit our Help page for information about searching for reporting guidelines and for general information about using our website.